bpc 157 peptide fda This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make FDA Just Changed the Future

In a phase 2 dose-finding trial, once-weekly Cagrilintide produced clinically meaningful weight loss about 10.8% at the 4.5 mg dose over 26 weeks with gastrointestinal effects the most common adverse events [1]

Neurological symptoms often develop gradually and may appear before anaemia is detected on blood tests

Lupus and Osteoporosis Compared with the general population, people with lupus are at an increased risk for osteoporosis, which is an accelerated loss of bone mass

Certain chemotherapy regimens, some antibiotics if taken for long periods, and long-term use of the epilepsy drug phenytoin, carry a risk of nerve damage